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Abstract: Progressive degeneration of neuroretinal tissue with maintained elevated intraocular
pressure (IOP) to simulate chronic glaucoma was produced by intracameral injections of poly (lactic-
co-glycolic) acid (PLGA) microspheres (Ms) in rat eyes. The right eye of 39 rats received different
sizes of PLGA-Ms (2 µL suspension; 10% w/v): 14 with 38–20 µm Ms (Ms38/20 model) and 25 with
20–10 µm particles (Ms20/10 model). This novel glaucoma animal model was compared to the
episcleral vein sclerosis (EPI) model (25 eyes). Injections were performed at baseline, two, four and
six weeks. Clinical signs, IOP, retina and optic nerve thicknesses (using in vivo optical coherence
tomography; OCT), and histological studies were performed. An IOP increment was observed in
all three groups, however, the values obtained from the PLGA-Ms injection resulted lower with a
better preservation of the ocular surface. In fact, the injection of Ms20/10 created a gentler, more
progressive, and more sustained increase in IOP. This IOP alteration was correlated with a significant
decrease in most OCT parameters and in histological ganglion-cell count for the three conditions
throughout the eight-week follow-up. In all cases, progressive degeneration of the retina, retinal
ganglion cells and optic nerve, simulating chronic glaucoma, was detected by OCT and corroborated
by histological study. Results showed an alternative glaucoma model to the well-known episcleral
vein model, which was simpler to perform, more reproducible and easier to monitor in vivo.
Keywords: PLGA microspheres; intraocular pressure; glaucoma animal model; intracameral injec-
tion; optic nerve; neurodegeneration
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1. Introduction
Glaucoma is a degenerative optic neuropathy in which irreversible vision loss is
produced by the gradual death of retinal ganglion cells (RGC). It has been estimated
that this neurodegenerative disease will affect up to 111.8 million people by 2040 [1].
Increased intraocular pressure (IOP) is the universal risk factor and IOP fluctuations have
been associated with immune-mediated progression of glaucoma [2–4]. However, the
mechanism by which elevated IOP leads to RGC death remains unclear.
In order to broaden and improve knowledge of glaucomatous pathologies, several an-
imal models have been developed in recent decades applying a significant increase in IOP
secondary to a decrease in outflow of aqueous humor. To this, either laser, cauterization,
ligature and/or episcleral vein sclerosis or mechanical blockage of the trabecular mesh-
work with obstructive substances (hyaluronic acid or paramagnetic, latex or polystyrene
beads injected into the anterior chamber) have been used [5]. All these models produce
a sudden, short increase in IOP resulting in limited RGC and axonal damage. Studies
using non-biodegradable beads to create glaucoma animal models include a wide range of
particle sizes, concentrations of administered suspensions and injection frequencies [6–13].
Although injections of these particles into the anterior chamber have been reported as
causing RGC and optic nerve degeneration, undesired effects such as synechia and corneal
opacity were also reported [14].
Although optic nerve degeneration and RGC apoptosis have been analyzed in glau-
coma models using histological studies and computational technologies [15–17], discrepan-
cies in retinal death distribution still remain. Furthermore, recent studies have even shown
immune-mediated [18] contralateral eye degeneration [17].
The biodegradable aliphatic polyester co-polymer poly (lactic-co-glycolic) acid (PLGA)
is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines
Agency for several clinical applications, mainly for drug delivery systems [19]. In an
aqueous environment, PLGA degrades by hydrolysis, producing lactic and glycolic acid
metabolized by Krebs’s cycle to CO2 and H2O being easily eliminated from the body [20].
In ophthalmic therapy, there is already an intraocular PLGA implant approved for
clinical use (Ozurdex) [21]. This biodegradable polymer can also be used to produce
microspheres (Ms). For several decades now, intraocular administration of Ms loaded with
different active substances has been under evaluation as a therapeutic tool for diseases
affecting the posterior segment of the eye [20,22]. The degradation rate of PLGA Ms ranges
from weeks to months and is influenced by tunable factors such as polymer molecular
weight, lactic:glycolic ratio, Ms size and shape, porosity, and pH environment [23,24].
This paper presents a new chronic animal glaucoma model created with repeated
injections of biodegradable nonloaded PLGA Ms into the anterior chamber of rat eyes. This
produces a progressive and chronic increase in IOP (up to eight weeks) and, consequently,
a neurodegenerative process that simulates the conditions appearing in glaucoma patients.
To our knowledge, nonloaded biodegradable microspheres have never been used for this
purpose until now. The developed animal model shows a degeneration of photoreceptors
and retinal ganglion cells that simulates human glaucoma.
2. Materials and Methods
2.1. Materials
Poly (D,L -lactide-co-glycolide) (PLGA) (50:50; inherent viscosity: 0.16–0.24 dL/g) was
obtained from Evonik España, Granollers, Spain. Polyvinyl alcohol (PVA; 67,000 g/mol)
(purchased from Merck KgaA, Darmstadt, Germany) and methylene chloride (obtained from
Pan Reac Appli Chem, Barcelona, Spain) were also employed in microsphere manufacture.
2.2. Manufacture of PLGA Microspheres
The PLGA Ms were obtained using the oil-in-water (O/W) emulsion solvent extraction-
evaporation technique. Thus, PLGA (400 mg) was first dissolved in methylene chlo-
ride (2 mL). Once dissolved, the organic polymer solution was emulsified with 5 mL of
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PVA Milli-Q water solution (1% w/v) using a homogenizer (Polytron RECO, Kinematica,
GmbHT PT3000, Lucerne, Switzerland) at 7000 rpm for 1 min. The emulsion formed was
then poured into 100 mL of PVA Milli-Q water solution (0.1% w/v) and magnetically stirred
for 3 h to allow organic solvent evaporation and, subsequently, Ms maturation.
Afterwards, the Ms were washed with Milli-Q water to remove the PVA and were
separated into two granulometric fractions (38–20 µm and 20–10 µm) using three sieves
(mesh size 38, 20 and 10 µm). Finally, the Ms were freeze-dried (freezing: −60 ◦C/15 min;
drying: −60 ◦C/12 h/0.1 mBar) and stored at −30 ◦C in dry conditions until use.
2.3. Microsphere Characterization
2.3.1. Production Yield Percentage (PY%)
The production yield percentage was calculated using the following Equation (1):
PY% = (amount of microspheres)/(total amount of polymers) × 100 (1)
2.3.2. Morphological Evaluation
Morphological evaluation was performed on the freeze-dried Ms using scanning
electron microscopy (SEM; Jeol, JSM-6335F, Tokyo, Japan). Gold sputter-coating was
applied to the samples prior to observation.
2.3.3. Mean Particle Size and Particle Size Distribution
Dual light scattering (Microtrac S3500 Series Particle Size Analyzer, Montgomeryville,
PA, USA) was employed to determine mean particle size and particle size distribution.
Three different measurements of each sample were obtained. The results were expressed
as volume mean diameters (±standard deviation).
2.4. Animals
All work with animals was approved by the Ethics Committee for Animal Research
(PI34/17, 27 June 2017) and was carried out in strict accordance with the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision Research on the premises of the
Biomedical Research Center of Aragon (CIBA). The animals were housed under controlled
conditions (12-h dark/light cycle, temperature 22 ◦C, relative humidity 55%). Standard
cages with environmental enrichment, water and food ad libitum were used.
Sixty-four Long Evans rats (40% males, 60% females) aged 4 weeks and weighing
50–100 g at the beginning of the experiment were used for this longitudinal and interven-
tionist study. Long Evans rats were used as being easy handling and for comparison with
previous studies having used these animals in glaucoma research and retinal degenera-
tion [3,18,25–27].
2.5. Ocular Hypertension (OHT) Induction
All animals received a total of 4 ocular hypertension injections administered in the
right eye (RE) at baseline, 2, 4 and 6 weeks under intraperitoneally sedative (60 mg/kg of
Ketamine + 0.25 mg/kg of Dexmedetomidine), along with topical eye drops containing
tetracaine 1 mg/mL + oxibuprocaine 4 mg/mL (Anestesico doble Colircusi, Alcon Cusí SA,
Barcelona, Spain), under aseptic surgical conditions (iodized solution and erythromycin
5 mg/g ointment (Oftalmolosa Cusí eritromicina, Alcon Cusí SA, Barcelona, Spain)).
Temperature was controlled using warm pads. Twenty-five animals received a sclerosing
injection in the episcleral veins as previously described [28]. The other animals received
PLGA Ms (2 µL suspension, 10% w/v) injected into the anterior chamber of the eye by
superotemporal corneal puncture: 14 animals received Ms38/20 and 25 animals received
Ms20/10. Injections were performed using a micrometered Hamilton syringe with a
glass micropipette.
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The injection was always done by an expert ophthalmologist using the same entrance
door in the peripheral cornea, so the cornea was altered as little as possible. There were no
central corneal leukomas that altered the corneal hysteresis.
2.6. Ophthalmological Studies
2.6.1. In Vivo
Clinical signs such as ocular surface redness, corneal alterations, intraocular inflam-
mation, infection or cataract formation, as well as IOP measurements using a Tonolab
tonometer (Tonolab, TiolatOy Helsinki, Finland), were recorded every week. This proce-
dure was accomplished using a sedative mixture of 3% sevoflurane gas and 1.5% oxygen
for less than 3 min in order to avoid hypotension effects, as recommended by other au-
thors [29]. The IOP value was obtained by averaging three consecutive measurements,
taken from the average of 6 rebounds.
Neuroretinal structures were analyzed using optical coherence tomography (OCT
Spectralis, Heidelberg Engineering, Heidelberg, Germany). Observations were performed
at baseline and then biweekly up to week 8. A plane contact lens was adapted to the
rat’s cornea to acquire high quality images. The protocols employed were as follows:
retina posterior pole (R), retina nerve fiber layer (RNFL) and ganglion cell layer (GCL)
with automatic segmentation. These protocols analyzed a circular area centered on the
optic disc using 61 b-scans. Subsequent follow-up examinations were performed at this
same location using the eye-tracking software and follow-up application. The retina and
GCL were analyzed on the basis of the 9 ETDRS (Early Treatment Diabetic Retinopathy
Study) areas [30], which included a central (C) 1-mm circle centered on the optic disc
(though no fovea exists in rats) and inner (inferior; II; superior: IS; nasal: IN; temporal:
IT) and outer (inferior: OI; superior: OS; nasal: ON; temporal: OT) rings measuring 2
and 3 mm in diameter, respectively, as well as total volume (TV). The RNFL protocol
provided measurements of the 6 peripapillary sectors (inferotemporal: IT; inferonasal:
IN; superotemporal: ST; superonasal: SN; nasal: N; and temporal: T). Retinal thickness
composed from the inner limiting membrane to the retinal pigment epithelium; RNFL from
the inner limiting membrane to the GCL boundaries; and GCL from the RNFL to the inner
nuclear layer boundaries.
2.6.2. Postmortem
Under general anesthesia, the animals were euthanized with an intracardiac injection
of sodium thiopental (25 mg/mL). Enucleated eyes used for histology and immunohis-
tochemistry were fixed in neutral buffered formalin (10%) and embedded in paraffin. A
total of 18 REs belonging to 18 rats injected in the anterior chamber with Ms (20–10 µm
and 38–20 µm) and injected with a saline solution in the episcleral veins (6 eyes each) were
analyzed. As controls, the contralateral noninjected left eyes were used. Eyes embedded
in paraffin were trimmed to reach the optic nerve head. After that, 5-µm sections were
deparaffined, rehydrated and washed using H2O2 (10%) for 5 min (quenching) before
incubation (overnight at 4 ◦C) of the following primary antibodies: mouse anti-Brn3a
(Santa Cruz Biotechnology Inc., Dallas, TX, USA) at 1:50 dilution; and rabbit anti-glial
fibrillary acidic protein (GFAP) (DAKO, Bath, United Kingdom) at 1:1000 dilution. Then,
sections were incubated at room temperature (90 min) with specific secondary antibodies:
biotinylated horse anti-mouse at 1:50 dilution and biotinylated goat anti-rabbit at 1:100
dilution (Vector Laboratories, Burlingame, CA, USA). After that, incubation was performed
with ABC-HRP (Thermo Fisher Scientific, Waltham, MA, USA) at 1:50 dilution at room
temperature (90 min). In a next step, sections were washed before and after every incuba-
tion in phosphate buffered saline solution finally, staining of sections was performed with
diaminobenzidine (DAB) (3 min) and counterstained with Harrys Hematoxylin (Sigma-
Aldrich Corp., St. Louis, MO, USA) at room temperature (20 min). Ganglion cells were
counted in radial sections of the retina along 2 mm of a linear region of the ganglion cell
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layer, corresponding to four areas, two on each side of the optic nerve head. Images were
then analyzed by an operator blinded to the treatment groups.
To analyze the location of the microspheres in the eye, paraffin sections stained with
Hematoxylin/Eosin and with the fluorescent dye BODIPY (Invitrogen, Carlsbad, CA,
USA) at 1:50 dilution were used. Once located, the nature of the cells surrounding the
microspheres was analyzed by immunohistochemistry using rat anti-Mac2 (Cedarlane,
Burlington, NC, USA) at 1:50 dilution. After incubation with biotynilated anti-rat antibody
(Abcam, Cambridge, UK) at 1:250 dilution and Streptavidin Alexa Fluor 568 (Invitrogen,
Carlsbad, CA, USA) at 1:100 dilution, nuclear counterstaining was performed with Bis-
benzimide (Sigma-Aldrich, Madrid, Spain) at 1:100 dilution and microscopic analysis
was performed using a laser-scanning confocal microscope (TCS SP2; Leica Microsystems
GmbH, Heidelberg, Germany). Procedural immunohistochemistry controls were carried
out by omitting the primary antibody in a sequential tissue section.
A total of 6 REs belonging to 6 rats injected in the anterior chamber with microspheres
(20–10 µm and 38–20 µm) and injected in the episcleral veins (2 eyes each) with a saline
solution were analyzed using transmission electron microscopy. As controls, the contralat-
eral noninjected left eyes were used. Retinal fragments were fixed in 2.5% glutaraldehyde
and 2% paraformaldehyde and then postfixed in 1% osmium tetroxide, stained in aqueous
uranyl acetate, dehydrated and embedded in epoxy resin. Ultrathin sections (70 nm) were
stained using lead citrate and examined using a transmission electron microscope (Jeol 1400,
Jeol Ltd., Tokyo, Japan).
For scanning electron microscopy, a total of 4 REs were fixed in 2.5% glutaralde-
hyde and dissected. The iridocorneal angle was exposed to examine the presence of
microspheres in the trabecular meshwork. After dehydration, samples were critical-point
dried, mounted on stubs, coated with gold-palladium, and observed in a scanning elec-
tron microscope (JEOL JSM-5410, Tokyo, Japan) at an acceleration voltage of 20 kV using
Semaphore software, Digital Micrograph v2.32, Gatan, Inc, Pleasanton, CA, USA (JEOL)
for image acquisition.
2.7. Statistical Analysis
Data were recorded in an Excel database and statistical analysis was performed
using SPSS software version 20.0 (SPSS Inc., Chicago, IL, USA). The Kolmogorov–Smirnov
test was used to assess sample distribution. Nevertheless, due to the non-parametric
distribution of most of the data, the Mann–Whitney U test was employed to evaluate
the differences between both cohorts. A paired Wilcoxon test was also employed for
change comparison recorded in each eye over the study period. Values were expressed as
means (±standard deviations). Values of p < 0.05 were considered to indicate statistical
significance. In order to avoid a high false-positive rate the Bonferroni correction for
multiple comparisons was also calculated. The level of significance for each variable was
established according to Bonferroni calculations (expressed as #). Statistical analysis of the
number of ganglion cells was conducted on the GraphPad Prism 5 software (GraphPad
Software, Inc., La Jolla, CA, USA) using one-way ANOVA. The results are shown as
mean ± SEM. Values of p < 0.05 were considered to indicate statistical significance.
3. Results
3.1. Production Yield, Mean Particle Size and Particle Size Distribution
The PLGA Ms prepared showed a production yield (PY) of 44.94 ± 1.60% for the
38–20 µm size range, while the 20–10 µm fraction resulted in a PY of 39.37 ± 1.75%. In
both cases, a monodisperse particle size distribution was observed in the selected size
range) (see Section 3.2). The mean particle size for the 38–20 µm fraction and the 20–10 µm
fraction resulted in 21.84 ± 1.26 µm and 14.07 ± 1.07 µm, respectively.
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3.2. Morphological Evaluation
According to the SEM images, both size fractions contained spherical particles in the








Figure 1. Visualization of microsphere (Ms) Scanning Electron Microscopy (SEM). (A) (SEM) images and poly (lactic-co-
glycolic) acid (PLGA) microsphere particle size distribution, 38–20 µm Ms (top); 20–10 µm Ms (bottom) and monodisperse
size distribution. Individual microspheres magnification 2500× and group microspheres 700× (B) Microsphere distribution
in the anterior chamber of a rat eye during follow-up. Abbreviations: p: pupil; r: light reflex; a: microspheres at inferior
iridocorneal angle; b: remnants of microspheres; c: microsphere pellet.
3.3. Ophthalmological Clinical Signs
No infection, intraocular inflammation (synechiae), cataract formation, or retinal
detachment were found in any OHT model. It is worth mentioning that the corneal surface
was better preserved in the Ms20/10 and Ms38/20 models than in the EPI model. As
can be observed in Figure 1B, microparticles showed a tendency to aggregate and were
localized at the inferior iridocorneal angle, sometimes forming a solid deposition (pellet).
This arrangement allowed a clear visual axis and, subsequently, correct OCT acquisition.
3.4. Localization of Microspheres in Injected Eyes
At eight weeks post-injection, a mixture of microspheres at different stages of biodegra-
dation formed aggregates at the iridocorneal angle, hampering the trabecular meshwork
(Figure 2). The microspheres were not colored in Hematoxilin/Eosin-stained sections,
appearing as transparent structures (Figures 2C and 3A). However, using the boron-
dipyrromethene (BODIPY) fluorescent dye, PLGA microspheres were specifically marked
in green (Figure 3B). Microsphere aggregates were stuck to the anterior surface of the iris
(Figures 2C and 3A). In contrast, only a few microspheres were in contact with the posterior
epithelium (endothelium) of the cornea (Figure 2C). Pigmented and unpigmented cells
appear inside aggregates surrounding the transparent microspheres (Figure 2C). These
cells were marked with the anti-Mac2 antibody (Figure 3C), indicating that they belong to
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the macrophagic cellular lineage [31]. SEM images corroborate the presence of aggregates
of microspheres and macrophages at the iridocorneal angle (Figure 2E,F).
Figure 2. Visualization of microspheres at the iridocorneal angle with Hematoxilin/Eosin and scan-
ning electron microscopy. (A–C) Localization of microspheres at the iridocorneal angle hampering
the trabecular meshwork. Hematoxilin/Eosin histological sections at the level of the optic nerve.
Arrowhead: microsphere in contact with the endothelium of the cornea. Scale bars for subfigure
(B) is 53.47 µm and for subfigure (C) is 6.73 µm. (D–F) Dissection of the iridocorneal angle. The
cornea has been sectioned and removed leaving the anterior eye chamber visible. Notice the whitish
appearance of the microspheres. (E,F) Scanning electron microscopy images. In (F) an aggregate of
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microspheres is visible at high magnification. This PLGA structure is partially covered by two
pseudopodia from a cell (colored in red) compatible with a macrophage. Scale bars for subfigure
(E) is 5.4 µm and for subfigure (F) is 1.66 µm. Abbreviations: ICA: iridocorneal angle; ON: optic
nerve; Tm: trabecular meshwork; Co: cornea; Ir: iris; L: lens; Ma: macrophage; CON: control eye;
Ms38/20: eye injected with Ms size 38–20 µm; Ms20/10: eye injected with Ms size 20–10 µm.
Figure 3. Identification of microspheres. (A) In Hematoxilin/Eosin-stained paraffin sections, microspheres (*) appeared
transparent and colorless. They were surrounded by cells, sometimes containing black pigment. (B) Microspheres were
specifically marked by boron-dipyrromethene (BODIPY) fluorescent dyes. (C) Double immunofluorescence using anti-
Mac2 antibody, a specific marker of macrophages, showed that microspheres were surrounded by macrophages. Nuclei
counterstained with Dapi. ICA: iridocorneal angle; Ir: iris; 38/20 and 20/10 µm microspheres. Scale bar: (A) 21.58 µm,
(B) 18.49 µm, (C) 18.49 µm.
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3.5. Intraocular Pressure (IOP)
No differences were found among cohorts at baseline in terms of IOP values. Repeated
injection of PLGA Ms into the anterior chamber produced continuous elevation of IOP.
While OHT was detected three weeks after the first injection in both microsphere models,
it was found from the first week onwards in the EPI model. The Ms38/20 model showed
more fluctuations in IOP values than the Ms20/10 model (Figure 4A). High percentages of
OHT eyes were found in all three models over time, although the EPI model showed the
highest percentages at nearly all times examined (see Figure 4B). Left eyes also showed an
increasing trend, albeit retarded (see Supplementary Materials: Figure S1).
Figure 4. Analysis of intraocular pressure (IOP). (A) Right eye IOP curve in ocular hypertensive
(OHT) models over follow-up. (B) Percentage of OHT right eyes (>20 mmHg) in the three OHT
models over follow-up. Abbreviations: EPI: episcleral sclerosis model; Ms38/20: 38/20 microsphere
model; Ms20/10: 20/10 microsphere model; RE: right eye; IOP: intraocular pressure; w: weeks, OHT:
ocular hypertension; (%): percentage; #: statistical significance p < 0.020, for Bonferroni correction for
multiple comparisons.
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3.6. Neuroretinal Examination
3.6.1. In Vivo OCT
Ms38/20: REs showed a progressive decrease in retina, RNFL and GCL thickness.
The thinnest sectors measured in the retina were the inner superior and inner temporal
sectors; in the RNFL it was the nasal sector; and in the GCL they were the inner temporal
and central sectors. Although a statistically decreasing trend was found in the retina and
GCL, the retina and RNFL parameters showed an increase in thickness in the transition
from weeks two to four (see Table S1). Left eyes (LEs) also experienced a statistical decrease
in thickness in the retina, RNFL and GCL at week eight in most retinal sectors, as well
as in the superotemporal sector of the RNFL and in the superior–inferior axis of the GCL
(see Table S2).
Ms20/10: REs showed a decreasing trend in retina, RNFL and GCL thickness up
to week eight. Although the retina protocol showed statistically significant decreased
measurements in the central, outer inferior and temporal sectors, as well as in total volume,
the inner superior retinal sector showed the lowest thickness at every examination. No
statistical differences were found in the RNFL, although the superior nasal and nasal sectors
exhibited the lowest thickness. Finally, the GCL showed significant statistical differences at
week eight compared to baseline in the central and inner superior sectors. Interestingly,
LEs showed even more OCT sectors with statistical decreases at week eight, while the
thinnest sectors in both Ms models were the same (see Table S2).
In the episcleral model, the retina, RNFL and GCL experienced fluctuations in thick-
ness throughout the study. Although the trend decreased in both eyes, no statistical
differences were found at week eight.
Comparison of OHT Models
The OHT models were compared. REs did not show any statistical differences in
retina and RNFL thicknesses at week eight; statistical differences were only found between
the EPI and Ms20/10 models in the central (18.92 ± 3.47 vs. 15.68 ± 2.23 µm, p = 0.006#),
inner inferior (26.25 ± 2.05 vs. 22.21 ± 4.32 µm, p = 0.009#) and inner temporal (23.50 ± 4.70
vs. 19.68 ± 3.74 µm, p = 0.047) sectors of the GCL.
The perceptual loss of thickness detected by OCT (change in thickness with respect
to the baseline measurement of each variable) was also analyzed. At the end of the study,
the Ms38/20 model showed the highest percentage thickness loss in all OCT parameters
in REs and in GCL in LEs. The GCL parameter experienced the greatest loss in each Ms
model. Both the EPI and Ms20/10 models experienced this RNFL > GCL > retina loss trend
in LEs. Nevertheless, no statistical differences in thickness were found between REs and
LEs in the Ms models (Figure 5A).
REs from the EPI and Ms38/20 models showed greater loss in the outer retinal sectors.
An I > S > N > T loss trend was found in the EPI model. Nevertheless, the retinal temporal
sector experienced the greatest percentage loss in both Ms models and in LEs in the EPI
model. In all models, both eyes showed greater percentage loss in the superior–inferior axis
sectors of the RNFL. The exception was the LE in the EPI model, which experienced the
inverse of the RE loss trend. Moreover, in all OHT models both eyes showed greater loss in
the inner sectors of the GCL, and REs in both the EPI and Ms20/10 models experienced the
same percentage loss trend by OCT sector (S > I > N > T) (see Figure 5B,C).
The RE loss rate per day and IOP increase in mmHg per week were calculated from
the average of all OCT sectors and expressed in µm/mmHg/day. The Ms38/20 model
experienced the highest loss rate (on average) in the retina, RNFL and GCL over the
study and at most examinations. The Ms20/10 model experienced a gentle, progressive
and sustained decrease from weeks two to eight. This did not occur with the EPI model,
which in the earliest examinations (weeks two and four) even showed an increase in the
RNFL and GCL. The EPI and Ms20/10 models experienced similar loss rates in RNFL
(0.0033 vs. 0.0030 µm/mmHg/day) at the end of the study (week eight) (see Table S3).
Pharmaceutics 2021, 13, 237 11 of 20
Figure 5. Percentage loss of neuroretinal structure identified by optical coherence tomography (OCT). (A) Percentage
loss of retina, retinal nerve fiber and ganglion cell layers in the three ocular hypertensive models; (B) nomenclature of
the neuroretinal sectors using OCT. (C) Neuroretinal percentage loss in OCT sectors and loss trend at 8-week follow-up.
Abbreviations: R: retina; C: central; II: inner inferior; OI: outer inferior; IS: inner superior; OS: outer superior; IN: inner
nasal; ON: outer nasal; IT: inner temporal; OT: outer temporal; RNFL: retina nerve fiber layer; IT: inferior temporal; IN:
inferior nasal; ST: superior temporal; SN: superior nasal; N: nasal; T: temporal; GCL: ganglion cell layer complex; RE:
right eye; LE: left eye; EPI: episcleral sclerosis model; Ms38/20: 38/20 microsphere model; Ms20/10: 20/10 microsphere
model; TV: total volume; I: inferior; S: superior; N: nasal, T: temporal; >: higher loss than; (%): percentage; OCT: optical
coherence tomography.
As comparable results were found between the EPI and Ms20/10 models, deeper
analysis was performed to determine which model was more aggressive or induced neu-
roretinal damage earlier. Statistical differences were only found in 12 of the 135 parameters,
and in 10 of them the Ms20/10 model showed lower thickness up to week eight (see
Table S4). Figure 6 shows the neuroretinal changes in the REs based on average percent-
age of thickness loss up to week eight. The EPI model had the most intense and rapid
loss in RNFL thickness from weeks four to six. Although the Ms20/10 model showed a
progressive decrease, it produced the greatest percentage loss in GCL later on.
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Figure 6. Changes in thickness percentage loss measured by optical coherence tomography (OCT) in two ocular hypertensive
(OHT) models. Abbreviations: EPI: episcleral sclerosis model; Ms20/10: 20/10 microsphere model; RNFL: retina nerve fiber
layer; GCL: ganglion cell layer complex; w: week; %: percentage.
3.6.2. Postmortem Examination
At eight weeks postinjection, retinal morphology was analyzed in the hypertensive rat
models. No obvious histological signs of retinal degeneration were observed (Figure 7A).
However, ultrastructural analysis showed a process of ganglion cell and photoreceptor
degeneration (Figure 7B,C). Common lesions observed in ganglion cells in all the hyperten-
sive models were indentations of the nuclear membrane and cytoplasmic vacuolization
(Figure 7B). Furthermore, as occurs in experimental glaucomatous mice after injection of
microbeads in the anterior chamber [32], the axonal mitochondria of ganglion cells in all hy-
pertensive rat models were enlarged and degenerated, showing fewer cristae (Figure 7C).
Brn3a-positive ganglion cells were counted in radial sections of the retina along 2 mm
of a linear region of the ganglion cell layer. These corresponded to four areas, two on
each side of the optic nerve head (Figure 7A) No significant differences in the number of
ganglion cells were found among the hypertensive models (EPI 23.51 ± 2.59 vs. MSs38/20
24.50 ± 2.96 vs. MSs20/10 23 ± 1.15 mean number of ganglion cells per linear mm of
retina, n = 6, p = 0.901) (Figure 7A). Micronuclei and loss of heterochromatin were observed
in the rod photoreceptors of all hypertensive models. Increased expression of GFAP in
cytoplasmic prolongations of Müller cells (gliosis) was observed in the entire retina of all
hypertensive models (Figure 8).
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Figure 7. Neurodegeneration of (A) ganglion cell layer, (B) somas and (C) axons. (A) Ganglion cell analysis. Ganglion
cells were counted in radial sections of the eye along 2 mm of a linear region of the retina. These corresponded to four
areas, two on each side of the optic nerve (ON). Nuclei of ganglion cells were marked with anti-Brn3a. Right image: mean
number of ganglion cells per linear mm of retina. Scale bars: 27.73 µm. (B) Degeneration of ganglion cells in OHT models at
8 weeks. Nuclear and nucleolar ultrastructural alterations, including indentations of the nuclear membrane and cytoplasmic
vacuolization were observed in all OHT models. Scale bars: 1.13 µm. (C) Enlarged mitochondria (arrows) were observed in
the axons of ganglion cells in all OHT models at 8 weeks. Scale bars: 0.29 µm. Abbreviations: EPI: right eyes injected in the
episcleral vein; Ms38/20: right eyes injected with 38–20 µm microspheres; Ms20/10: right eyes injected with 20–10 µm
microspheres; RGC: ganglion cell; CON: right eye from a nontreated rat; GC: ganglion cell; ILM: internal limiting membrane.
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Figure 8. Overexpression of GFAP (gliosis) was observed in retinas of all ocular hypertensive (OHT) right eyes at 8 weeks.
Note the expression of GFAP in the cytoplasmatic prolongations of Müller cells (arrows). The retinas of contralateral
(left) eyes also showed gliosis, although the expression of GFAP by Müller cells was lower. Abbreviations: CON: repre-
sentative retinal section from a contralateral (left) eye; EPI: representative retinal section from a right eye injected in the
episcleral vein; Ms38/20: representative retinal section from a right eye injected with 38–20 µm microspheres; Ms20/10:
representative retinal section from a right eye injected with 20–10 µm microspheres; GCL: ganglion cell layer; INL: inner
nuclear layer; ONL: outer nuclear layer.
4. Discussion
To our knowledge this is the first study focused on the intracameral injection of
biodegradable PLGA Ms as a method to induce chronic ocular hypertension. In this work
we analyzed two different Ms sizes (small: 20/10; and large: 38/20) and compared them
with the well-established Morrison model (EPI) [28]. Although in many previous studies
researchers injected beads into the anterior chamber, they all used non-biodegradable
materials [5]. This is the case of [8] the glaucomatous effect comparison after injecting a
suspension (2 microliters) of non-biodegradable polystyrene microparticles of different
sizes and concentrations: 10 microns (106 beads/mL) and 15 microns (5 × 106 beads/mL)
into the anterior chamber. In that study, the small microparticles (10 microns) produced
a greater and more sustained increase in IOP than the large ones (15 microns), which
only increased IOP for two weeks. In the present study, the repeated injection of the two
particle size fractions tested (20–10 µm and 38–20 µm) produced an increase in IOP after
Ms injection followed by a decrease at one week resulting in fluctuating IOP values. The
larger Ms (Ms38/20) produced greater fluctuations and resulted in both lower final IOP
and greater degenerative loss as evaluated by OCT at eight weeks. This suggests that
fluctuations in IOP could play an important role as an accelerator of the disease [2].
In this study, a comparison with a cohort injected with the vehicle employed to create
the particle suspensions (saline solution) was not performed as other authors have already
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demonstrated that axon density in the nerves injected with saline did not differ from the
ones observed in naive nerves [6].
In order to compare results between the different models, the authors decided to
carry out biweekly injections. According to the results obtained, reinjection of Ms resulted
in the accumulation of particles in the administration site accompanied by progressive
in situ degradation. This combination of factors probably produced obstructions in the
trabecular meshwork, generating a gradual increase in IOP. It is worth mentioning that the
injection of the smaller Ms avoided potential peaks and postinjection variability. Although
these factors mainly occur after episcleral injections, they are also produced by injection of
large Ms. According to the results observed, injection of Ms20/10 created a gentler, more
progressive and more sustained increase in IOP that focused the harmful effect of OHT
and allowed it to be isolated.
In the present work, after intracameral injection of PLGA Ms, a whitish material
and aggregation of particles were observed in the aqueous humor. Both phenomena were
similar to those described after intravitreal injection of PLGA particles [33,34]. Furthermore,
it is important to remark that the repeated injections of Ms (0.2 mg/injection) increased
the amount of PLGA at the administration site, resulting in a total of 0.8 mg by the end
of the study (eight weeks), therefore with the particles in different stages of degradation.
The remains of microspheres were observed in the biweekly reinjections and until the end
of the study (eight weeks). The frequency of the injections made it impossible to know if
the remains belonged to two, four, or six weeks, however the visualization of remnants
of different sizes suggested a durability of at least more than four weeks. The different
shapes found in the site of injections can be explained from the biodegradation process
of the PLGA particles. In fact, it has been previously reported that PLGA microspheres’
morphology changes over time. For example, in a previous study, authors observed that
microparticles prepared with the same polymer used in the present work were able to
maintain their spherical shape up to two weeks after incubation in PBS and that from
four weeks onwards the particles suffered erosion and shape loss [35], coinciding with
our findings.
Our histological results also demonstrated macrophage affectation and activation
by PLGA Ms (Figure 2F), this time inside the anterior chamber of the rat eye. Other
authors [33] described a localized foreign body reaction partially surrounding the degraded
PLGA microspheres after intravitreal injection. Histologic studies also demonstrated the
presence of mononuclear cells and multinucleated giant cells with no involvement of
the retina [36]. The reaction described by these authors is similar to the one observed
after intramuscular injection of microspheres in rabbits, decreasing over time. It has been
reported that macrophages have the ability to phagocytize PLGA particles with sizes below
10 µm [37] and that these effector cells at the interface of the biodegradable microspheres can
produce acid and other agents and may decrease interfacial pH [34]. PLGA microspheres
as ocular drug delivery carriers are intended to avoid frequent injections. Therapeutic use
of microspheres also includes drug loading, different to the blank microspheres used in
this work. In the present study, the amount of microspheres at the trabecular meshwork
and the frequent injections caused an inflammatory response which was accompanied
by macrophages at the surface of the microspheres (Figure 2). As described by other
authors, macrophages at the interface of the biodegradable microspheres can produced
acidic concentrations and low the pH of the extracellular fluids [37]. It should be noted
that an acidic environment is also present in glaucoma, supporting the advantage of using
nonloaded PLGA microspheres to create glaucoma animal models. It is important to
remark that the behavior of nonloaded and loaded PLGA microspheres is different as the
microenvironment pH created as a result of the injection of the loaded particles depends
not only on the polymer but also the drug. In fact, it has been demonstrated that the use of
basic drugs or additives can led to a pH increase and that appropriate amounts of basic
substances can neutralize carboxylic end groups [38].
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Evaluation using OCT revealed that the increase in IOP resulted in neuroretinal
loss both in the inner sectors of the GCL and in the sectors of the superior–inferior axis
of the RNFL, as several authors found [15,17,28], but contrary to the findings of other
authors [8,18] that detected peripheral loss. These discrepancies between studies might
be due to retinal growth of the eye at the expense of peripheral areas [39]. A rate of RNFL
loss similar to that reported by other authors [15] was also found, occurring in both the
episcleral model and in the Ms20/10 model, which supports the reproducibility of our
results and the similarity between the models in this eight-week study.
Recent studies have demonstrated bilateral neurodegeneration following unilateral
induction of hypertension using different models such as episcleral vein sclerosis, cauteriza-
tion of episcleral veins and of the trabecular meshwork, or an intermittent loop [3,17,18,40].
It is generally accepted that glaucomatous damage is a consequence of axonal degeneration
that leads to retinal ganglion cell death. Glial activation is also present in glaucoma [41].
The affectation of microglia in neurodegeneration and its progression have been demon-
strated [18] in previous methods for inducing hypertension. All of them are aggressive and
produce sudden increases in IOP, which suggest the presence of an immune reaction to
a stressor. However, it has also been recently suggested that latent inflammation would
worsen retinal degeneration [42], as we found in our results, which showed increased
gliosis even in Ms models that produced gentle increases in IOP. The present work would
be the first study demonstrating that a gentle and sustained increase in IOP also resulted
in contralateral retinal damage, as shown by the neuroretinal decrease revealed by OCT
and the fact that, despite the decrease in the number of RGC, no statistical differences were
found between the eyes (contralateral eye and induced eye) (Figure 7A). This could be
due to the use of the opposite eye as a control in our study. As we previously mentioned,
several authors have recently demonstrated the involvement of the opposite eye after the
induction of ocular hypertension [3,17,18,40], so it is recommended to take this aspect into
account or to use healthy animals for comparison in future studies. Other authors have
already shown that a small increase in IOP, relative to the contralateral eye, could trigger
the T-cell-mediated neurodegenerative process [4]. This damage has been detected after
24 h in the induced eye [40] and after one week in the uninduced contralateral eye [17]. In
this study, OCT showed neuroretinal loss from the first interim scan (two weeks), though
it could possibly be detected even earlier. As glial activation is now known to spread via
the visual pathway, degenerative factors could, in turn, activate the laminar and prelami-
nar glia [43] of the contralateral eye, producing retrograde damage and also creating an
imbalance in pressure in the optic nerve head [44]. On the other hand, in addition to this
damage to the neuroretinal structure, a gradual increase in IOP was also detected in the
uninduced contralateral eye, as also found by other authors [18,45].
It is important to remark that injection of PLGA Ms in the anterior chamber is an easy
surgical technique to generate OHT and, moreover, adequately maintains ocular structures,
making this a simple, useful and efficient hypertensive model. In this study, the small
volume of only 2 µL was chosen to avoid a significant increase in the initial intraocular
pressure and to facilitate a more progressive mechanical blockage of the particles in the site
of injection. In a previous work, it was shown that an injection volume of 2.5 mL of saline
solution generated IOP fluctuations about a consistent baseline and also that volumes up
to 7 µL could even be administered since the values of the mean IOP for the eyes injected
with saline did not depend on injection volume [6].
In the current study, the importance of the administration route and the nature of
the device in the observed effect has also been demonstrated. The intracameral route is
used for the administration of antibiotics and recently several intracameral implants are
undertaking clinical trials or are already commercialized [46]. In the case of implants
and from a clinical point of view, one of the side effects of the intracameral implantation
is related to the iridocorneal angle. In fact, the use of therapeutic devices such as the
case of Durysta, an implant made from PLGA and bimatoprost (Allergan, Irvine, CA,
USA), is restricted in patients with small angle or any issue that could promote the deposit
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of the device in the inferior angle [46]. Taking into account this mentioned side effect,
we used the microspheres to promote an obstruction of the trabecular meshwork which
in turn promotes an increase of IOP. Furthermore, the aggregation of the administered
particles and their high frequency of injection (baseline, two, four and six weeks) allow
the microspheres to remain longer in the site of injection. This produces a mechanical
blockage that has been previously described in other studies by using non-biodegradable
particles [6–8]. It is worth mentioning that in this case the injection of the microparticles is
not used for therapeutic purposes and also that the aggregation at the iridocorneal angle
is one of the causes of the increase of IOP. By using other administration routes, mainly
intravitreal and periocular, PLGA microspheres have demonstrated their potential for the
treatment of several ocular diseases due to the ability of these systems to deliver multiple
active substances directly to the target site during the long term [20,22]. Previous studies
have demonstrated that microspheres for therapeutic purposes were well tolerated after
intravitreal injection [20,35,47,48]. The amount of PLGA microspheres is also an important
factor to be considered. Other studies have shown that a high quantity of microspheres can
induce retinal damage, being well tolerated if low amounts of these drug delivery systems
are used [49]. In the present study microspheres were injected every two weeks resulting
in a total of 0.8 mg (high quantity in rat trabecular meshwork) at the end of the study.
Based on the results obtained in the present work we could predict that future
studies with longer follow-up times and less neurodegenerative damage (by modula-
tion/minimization of reinjection) would allow getting closer to real-world glaucoma
models. Chronic glaucoma animal models are of great interest for the study of the differ-
ent phases and stages of glaucoma, and to test new treatments based on long-term drug
delivery systems.
In conclusion, this study describes a new glaucoma model using biodegradable PLGA
microspheres injected into the anterior chamber of the eye that causes a progressive increase
in IOP and neuroretinal degeneration like the ones observed in the episcleral vein model.
This study paves the way for new models of neuroretinal degeneration using a method that
is simpler to perform and more reproducible than episcleral vein injection. This model is
also less aggressive to the surface of the animal’s eye, thereby making transparent structures
available in that eye. This fact allows repeated evaluation by noninvasive technology such
as OCT to monitor the development of the pathology generated and to quantify in an
objective and nonharmful way the effectiveness of new therapies to treat glaucoma.
Supplementary Materials: The following are available online at https://www.mdpi.com/1999-492
3/13/2/237/s1, Figure S1: (A) Left eye IOP curve in the OHT models during follow-up. (B) Percent-
age of OHT left eyes (>20 mmHg) in the three OHT models during follow-up. EPI: episcleral sclerosis
model; Ms38/20: 38/20 microsphere model; Ms20/10: 20/10 microsphere model; LE: left eye; IOP:
intraocular pressure; w: weeks; OHT: ocular hypertension; (%): percentage; *: statistical significance
p < 0.050; #: statistical significance p < 0.020 for Bonferroni correction for multiple comparisons,
Table S1: Structural neuroretinal analysis using OCT with the Ms38/20 model. Ms38/20: 38/20
microsphere model; RNFL: retina nerve fiber layer; GCL: ganglion cell layer complex; thickness in
microns (µm); mean ± SD (SD: standard deviation); *: p < 0.050 statistical significance; #: p < 0.020
statistical significance with Bonferroni correction for multiple comparisons. Grey cells show the two
thinnest sectors at every examination, Table S2: Left eye neuroretinal analysis using OCT in both
microsphere models at week 8. Ms38/20: 38/20 microsphere model, Ms20/10: 20/10 microsphere
model; RNFL: retina nerve fiber layer; GCL: ganglion cell layer complex; thickness in microns (µm);
mean ± SD (SD: standard deviation); *: p < 0.050 statistical significance; #: p < 0.020 statistical
significance with Bonferroni correction for multiple comparisons; w: week. Grey cells show the two
thinnest sectors at every examination, Table S3: Right eye neuroretinal loss rate measured using OCT
in the OHT models. EPI: episcleral sclerosis model; Ms38/20: 38/20 microsphere model; Ms20/10:
20/10 microsphere model; RNFL: retina nerve fiber layer; GCL: ganglion cell layer complex; RE:
right eye; thickness in microns (µm); w: week. Grey cells show the lowest measurements, Table S4:
Right eye neuroretinal analysis follow-up using OCT in both OHT models. EPI: episcleral sclerosis
model; Ms20/10: 20/10 microsphere model; RNFL: retina nerve fiber layer; GCL: ganglion cell layer
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complex; thickness in microns (µm); mean ± SD (SD: standard deviation); % Ch: percentage change
in thickness loss; *: p < 0.050 statistical significance; #: p < 0.020 statistical significance with Bonferroni
correction for multiple comparisons; w: week. Cells colored grey when EPI model showed thinner
sectors and/or higher percentage loss compared to Ms20/10.
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